The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers
Stijn Moens(VIB-KU Leuven Center for Cancer Biology), Frédéric Amant(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)
Cited by 27
Related Papers
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
|International Journal of Gynecological Cancer|2015|757
Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients
|The Lancet Oncology|2018|371
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
|Annals of Oncology|2024|277
Ovarian cancer
|Critical Reviews in Oncology/Hematology|2006|218